These are busy times for the folks at Oleg Nodelman’s EcoR1 Capital, an investment firm focused on therapeutic companies in the biotechnology sector.
Silverback Therapeutics, a clinical-stage biopharmaceutical company backed by EcoR1 Capital, filed plans with regulators this week to go public. On the same day, EcoR1-backed Oric Pharmaceuticals announced it was raising capital through a public offering of four million shares of common stock.
